Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.38 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.38 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.38 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.36 |
| ▸ | CCR5 known ✓ | P51681 | 1/20 | 0.35 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RHEB | Q15382 | 3/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2771553 | 0.99 | SMN1; SMN2 (0.40) | HTTSMN1; SMN2LMNAMAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL2768923 | 0.87 | AOC3 (0.51) | HTTSMN1; SMN2LMNAMAPTL3MBTL1 | |
| SCHEMBL2769084 | 0.86 | MEN1 (0.41) | HTTSMN1; SMN2LMNAMAPTL3MBTL1 | |
| SCHEMBL2771388 | 0.85 | AOC3 (0.49) | HTTSMN1; SMN2LMNAMAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL2769962 | 0.83 | INPPL1 (0.43) | SMN1; SMN2LMNAMAPTL3MBTL1MEN1 | |
| SCHEMBL2768320 | 0.81 | INPPL1 (0.43) | SMN1; SMN2LMNAMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL2769608 | 0.77 | ADRA2A (0.39) | AOC3MAOBACHEKMT2ARAB9A | |
| SCHEMBL2769381 | 0.75 | ADRA2A (0.40) | MAOBACHEKMT2ANPC1RAB9A | |
| SCHEMBL3592904 | 0.74 | HTR6 (0.42) | HTTSMN1; SMN2LMNAMAPTL3MBTL1 | |
| SCHEMBL5808896 | 0.74 | HTR6 (0.50) | HTTSMN1; SMN2LMNAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805177-B9 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2010-09-15 | — | — | EP | claimed |
| EP-1805177-B1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2010-04-28 | — | — | EP | claimed |
| EP-1805177-A4 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2009-07-29 | — | — | EP | claimed |
| US-7541366-B2 | Pyrrolo[3,2-c]pyridine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2009-06-02 | — | — | US | claimed |
| US-20070249658-A1 | Pyrrolo[3,2-C]Pyridine Deriatives and Processes for the Preparation Thereof | YUHAN CORPORATION (KR) | 2007-10-25 | — | — | US | claimed |
| EP-1805177-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2007-07-11 | — | — | EP | claimed |
| WO-2006025715-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2006-03-09 | — | — | WO | claimed |
| EP-1805177-B9 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2010-09-15 | — | — | EP | disclosed |
| EP-1805177-B1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2010-04-28 | — | — | EP | disclosed |
| CN-100564379-C | Pyrrolo-[3,2-C] pyridine derivate and preparation method thereof | YUHAN CORP (KR) | 2009-12-02 | — | — | CN | disclosed |
| EP-1805177-A4 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2009-07-29 | — | — | EP | disclosed |
| US-7541366-B2 | Pyrrolo[3,2-c]pyridine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2009-06-02 | — | — | US | disclosed |
| US-20070249658-A1 | Pyrrolo[3,2-C]Pyridine Deriatives and Processes for the Preparation Thereof | YUHAN CORPORATION (KR) | 2007-10-25 | — | — | US | disclosed |
| CN-101010322-A | Pyrrolo[3,2-C]pyridine derivatives and processes for the preparation thereof | YUHAN CORP (KR) | 2007-08-01 | — | — | CN | disclosed |
| EP-1805177-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006025715-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249658-A1 | Pyrrolo[3,2-C]Pyridine Deriatives and Processes for the Preparation Thereof | ATP6AP1, HPD, ATP6V1H | MAOB 1990/4885MAOA 2805/4885ACHE 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.